Company: NYXH
Filing Date: 2025-03-20
Form Type: F-3
Source: 0001104659-25-026217
Chunk: 63

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: F-3
Chunk 63
---
 of December 31, 2024 plus 5,662,694 ordinary shares, which is the maximum number of shares that our board of directors has approved for issuance in this offering. The number of shares outstanding excludes:

•

2,258,319 ordinary shares issuable upon exercise of warrants outstanding as of December 31, 2024 at a weighted average exercise price of €7.82 per ordinary share.

•

346,431 ordinary shares issuable upon exercise of warrants that are outstanding as of December 31, 2024 but not yet granted.

Unless otherwise indicated, all information in this prospectus supplement does not reflect and does not take into account:

•

any issuance of ordinary shares upon the exercise of warrants subsequent to December 31, 2024, including up to 805,000 ordinary shares issuable upon exercise of the warrants that our board issued on January 30, 2025 (of which 278,943 warrants have been granted prior to the date hereof).

<div align='center'>S-4</div>

TABLE OF CONTENTS

### RISK FACTORS
An investment in our ordinary shares involves a high degree of risk. Before deciding whether to invest in our ordinary shares, you should consider carefully the risks described below and discussed under the sections captioned “Risk Factors” contained in our most recent Annual Report on Form 20-F, which is incorporated by reference herein in its entirety, together with other information in this prospectus supplement, the information and documents incorporated by reference in this prospectus supplement, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our ordinary shares to decline, resulting in a loss of all or part of your investment.

Our business, financial condition, results of operations or cash flow could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose part or all of your investment. This prospectus supplement and the incorporated documents also contain forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors, including the risks mentioned below. Forward-looking statements included in this prospectus supplement are based on information available to us on the date hereof, and all forward-looking statements in documents incorporated by reference are based on information available